4//SEC Filing
Akinsanya Karen 4
Accession 0001209191-21-060945
CIK 0001490978other
Filed
Oct 18, 8:00 PM ET
Accepted
Oct 19, 5:00 PM ET
Size
8.9 KB
Accession
0001209191-21-060945
Insider Transaction Report
Form 4
Akinsanya Karen
President of R&D, Therapeutics
Transactions
- Exercise/Conversion
Common Stock
2021-10-15$4.34/sh+1,393$6,046→ 1,393 total - Exercise/Conversion
Stock Option (right to buy)
2021-10-15−1,393→ 43,198 totalExercise: $4.34Exp: 2028-11-29→ Common Stock (1,393 underlying) - Sale
Common Stock
2021-10-15$55.75/sh−1,393$77,660→ 0 total
Footnotes (2)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.
- [F2]This option was granted on November 29, 2018. The shares underlying the option vested with respect to 25% of the shares on December 31, 2019 and the remainder are scheduled to vest in equal monthly installments through December 31, 2022.
Documents
Issuer
Schrodinger, Inc.
CIK 0001490978
Entity typeother
Related Parties
1- filerCIK 0001797672
Filing Metadata
- Form type
- 4
- Filed
- Oct 18, 8:00 PM ET
- Accepted
- Oct 19, 5:00 PM ET
- Size
- 8.9 KB